Randomized clinical trials indicate that cholinesterase inhibitors benefit patients with mild, moderate, and severe AD,1 whereas memantine primarily benefits patients with moderate-to-severe AD.3 Consequently, it is a common practice to start cholinesterase inhibitor therapy and then add memantine once patients progress to moderate-to-severe dementia. Here, BCHE is linked to dementia.